{"nctId":"NCT03952039","briefTitle":"An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","startDateStruct":{"date":"2019-09-09","type":"ACTUAL"},"conditions":["Primary Myelofibrosis","Post-Polycythemia Vera","Myelofibrosis"],"count":202,"armGroups":[{"label":"Fedratinib 400mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: FEDRATINIB"]},{"label":"Best Available Therapy (BAT)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Best Available Therapy (BAT)"]}],"interventions":[{"name":"FEDRATINIB","otherNames":[]},{"name":"Best Available Therapy (BAT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject is at least 18 years of age at the time of signing the informed consent form (ICF)\n2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2\n3. Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post-PV myelofibrosis according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report\n4. Subject has a DIPSS Risk score of Intermediate-2 or High\n5. Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm3 by MRI or CT-scan and by palpable spleen measuring ≥ 5 cm below the left costal margin\n6. Subject has a measurable total symptoms score (≥ 1) as measured by the Myelofibrosis Symptom Assessment Form (MFSAF)\n7. Subject has been previously exposed to ruxolitinib, and must meet at least one of the following criteria (a and/or b)\n\n   1. Treatment with ruxolitinib for ≥ 3 months with inadequate efficacy response (refractory) defined as \\< 10% spleen volume reduction by MRI or \\< 30% decrease from baseline in spleen size by palpation or regrowth (relapsed) to these parameters following an initial response\n   2. Treatment with ruxolitinib for ≥ 28 days complicated by any of the following (intolerant):\n\n      * Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) or\n      * Grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib\n8. Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to randomization\n9. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted\n10. Subject is willing and able to adhere to the study visit schedule and other protocol requirements\n11. A female of childbearing potential (FCBP) must:\n\n    1. Have 2 negative pregnancy tests as verified by the Investigator during screening prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact.\n    2. Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with highly effective contraception without interruption, -14 days prior to starting investigational product, during the study treatment (including dose interruptions), and for 30 days after discontinuation of study treatment.\n\n    Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).\n12. A male subject must:\n\nPractice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 30 days following investigational product discontinuation, or longer if required for each compound and/or by local regulations, even if he has undergone a successful vasectomy\n\nExclusion Criteria:\n\n1. Any of the following laboratory abnormalities:\n\n   1. Platelets \\< 50 x 109/L\n   2. Absolute neutrophil count (ANC) \\< 1.0 x 109/L\n   3. White blood count (WBC) \\> 100 x 109/L\n   4. Myeloblasts ≥ 5 % in peripheral blood\n   5. Estimated glomerular filtration rate \\< 30 mL/min/1.73 m2 (as per the Modification of Diet in Renal Disease \\[MDRD\\] formula)\n   6. Serum amylase or lipase \\> 1.5 x upper limit of normal (ULN)\n   7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 x upper limit of normal (ULN)\n   8. Total bilirubin \\> 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is \\< 25% of the total bilirubin\n2. Subject is pregnant or lactating female\n3. Subject with previous splenectomy\n4. Subject with previous or planned hematopoietic cell transplant\n5. Subject with prior history of encephalopathy, including Wernicke's (WE)\n6. Subject with signs or symptoms of encephalopathy, including WE (eg, severe ataxia, ocular paralysis or cerebellar signs)\n7. Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to the central laboratory and not demonstrated to be corrected prior to randomization\n8. Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 3A4 (CYP3A4), or dual CYP2C19 and CYP3A4 inhibitors\n9. Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids \\> 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to randomization\n10. Subject has received ruxolitinib within 14 days prior to randomization\n11. Subject with previous exposure to Janus kinase (JAK) inhibitor(s) other than ruxolitinib treatment\n12. Subject on treatment with aspirin with doses \\> 150 mg daily\n13. Subject with major surgery within 28 days prior to randomization\n14. Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis)\n15. Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to randomization. However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis \\[TNM\\] clinical staging system), or is free of disease and on hormonal treatment only\n16. Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4)\n17. Subject with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC)\n18. Subject with serious active infection\n19. Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication\n20. Subject is unable to swallow capsule\n21. Subject with any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study\n22. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study\n23. Subject has any condition that confounds the ability to interpret data from the study\n24. Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to randomization\n25. Subject with a life expectancy of less than 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Spleen Volume Response Rate (RR)","description":"Percentage of participants who have ≥ 35% spleen volume reduction (SVR) at end of cycle 6\n\nA Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment).\n\nThe RRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in RRs and 95% confidence interval of the difference for fedratinib to BAT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptom Response Rate (SRR)","description":"Percentage of participants with ≥ 50% reduction in total symptom scores measured by Myelofibrosis Symptom Assessment Form (MFSAF) 4.0 at end of cycle 6.\n\nSubjects with a missing TSS at the end of cycle 6 or who had disease progression before the end of the cycle 6 will be considered non-responders.\n\nMFSAF measures the sum of 7 symptoms on a scale from 0 to 10 (0 being absent and 10 being the worst imagineable). The lower the score the better.\n\nA Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment).\n\nThe SRRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in SRRs and 95% confidence interval of the difference for fedratinib to BAT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"16.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Spleen Volume Response Rate (RR25)","description":"Percentage of participants who have ≥ 25% spleen volume reduction (SVR) at end of cycle 6\n\nA Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment).\n\nThe RRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in RRs and 95% confidence interval of the difference for fedratinib to BAT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.0","spread":null},{"groupId":"OG001","value":"13.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With All Grade Treatment Emergent Adverse Events (AEs) and Grade 3 to 4 Treatment Emergent AEs","description":"Number of participants with all grade adverse events (AEs) and grade 3 to 4 AEs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hematology Laboratory Abnormalities","description":"Number of participants with hematology laboratory abnormalities in the following parameters: hemoglobin (decreased), leukocytes (increase and decrease), lymphocytes (decreased), neutrophils (segmented and band form decreased), Platelets (decreased).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Spleen Response Rate by Palpation (RRP)","description":"Spleen response rate by palpation is the percentage of participants at the end of cycle 6 with a spleen response according to the IWG-MRT 2013 criteria.\n\nA baseline splenomegaly that is palpable at 5-10 cm, below the LCM, becomes not palpable\\*\\* or A baseline splenomegaly that is palpable at \\> 10 cm, below the LCM, decreases by ≥ 50%\\*\\*\n\nParticipants with a missing spleen size assessment at the end of cycle 6 including those who meet the criteria for progression of splenomegaly before end of cycle 6 will be considered not to be responders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Durability of Spleen Volume Response (DR)","description":"Durability of spleen volume response (DR) by MRI/CT is defined as the date from the first documented spleen response (ie, ≥ 35% reduction in spleen volume) to the date of subsequent progressive disease (PD) in spleen volume per the IWG-MRT 2013 criteria or death, whichever is earlier. In the absence of an event before the analysis is performed, the DR will be censored at the date of the last valid assessment performed before the analysis performed date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Durability of Spleen Response by Palpation (DRP)","description":"Durability of spleen response by palpation (DRP) is defined as time from the date of the first documented palpable spleen response, according to the IWG-MRT 2013 to the date of the subsequent PD in spleen size according to the IWG-MRT 2013 or death, whichever is earlier. Durability of spleen response by palpation according to the IWG-MRT 2013 criteria will be calculated for subjects that have an enlarged spleen at baseline (≥ 5 cm below LCM), and that have a spleen response by palpation. In the absence of an event before the analysis is performed, the DRP will be censored at the date of the last valid assessment performed before the analysis performed date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118.3","spread":null},{"groupId":"OG001","value":"47.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Durability of Symptoms Response (DSR)","description":"The DSR is defined as time from the first documented response in TSS (ie, reduction in TSS ≥ 50%) measured by MFSAF version 4.0 to the first documented TSS reduction \\< 50%. In the absence of TSS reduction \\< 50% before the analysis performed, the DSR will be censored at the date of the last valid assessment performed before the analysis performed date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"10.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of the Effectiveness of Risk Mitigation Strategy for ≥3 Grade Gastrointestinal Adverse Events and Any Grade Wernickes Encephalopathy","description":"Number of participants with a CTCAE Grade ≥3 of nausea, diarrhea, or vomiting and any grade wernickes encephalopathy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Thiamine Levels Below the Lower Limit of Normal","description":"Number of participants with thiamine levels below the lower limit of normal","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in EORTC QOL-C30 at Cycle 7 Day 1 as Compared With Baseline","description":"QLQ-C30 - The EORTC QLQ-C30 was developed to assess the quality of life of cancer patients. It consists of 30 items classified into 15 domains including 5 functional subscales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning); 3 multi-item symptom subscales (fatigue, nausea/vomiting, and pain); a global QOL subscale; and 6 single items addressing various symptoms and perceived financial impact. Scores vary from 0 (worst) to 100 (best) for the functional dimensions and GHS, and from 0 (best) to 100 (worst) for the symptom dimensions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"27.42"},{"groupId":"OG001","value":"13.1","spread":"26.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"19.57"},{"groupId":"OG001","value":"11.1","spread":"26.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"34.26"},{"groupId":"OG001","value":"12.7","spread":"40.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"19.63"},{"groupId":"OG001","value":"5.6","spread":"25.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"19.83"},{"groupId":"OG001","value":"5.6","spread":"17.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"29.18"},{"groupId":"OG001","value":"0.0","spread":"27.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.2","spread":"29.34"},{"groupId":"OG001","value":"-16.4","spread":"33.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"15.32"},{"groupId":"OG001","value":"-9.5","spread":"28.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.9","spread":"25.88"},{"groupId":"OG001","value":"-9.5","spread":"33.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"31.04"},{"groupId":"OG001","value":"-22.2","spread":"35.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.4","spread":"30.50"},{"groupId":"OG001","value":"-7.9","spread":"25.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.5","spread":"32.84"},{"groupId":"OG001","value":"-20.6","spread":"35.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"31.34"},{"groupId":"OG001","value":"-9.5","spread":"35.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"27.19"},{"groupId":"OG001","value":"6.3","spread":"17.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"21.03"},{"groupId":"OG001","value":"1.6","spread":"12.81"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in EQ-5D-5L Utility Index Score","description":"EQ-5D-5L - The EQ-5D-5L is a generic, self-administered preference-based measure of health. The five dimensions covered by the EQ-5D-5L include mobility, self-care, pain, usual activities, and anxiety/depression and is converted into a single summary index that can range from -0.594 to 1.0, with a score of 0 indicating death, 1.00 indicating \"full health,\" and negative scores reflecting states perceived to be worse than death. Respondent's self-rated health on a vertical, 0 to 100 scale where 100 = \"Best imaginable health state\" and 0 = \"Worst imaginable health state\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1086","spread":"0.20188"},{"groupId":"OG001","value":"0.0705","spread":"0.22881"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1093","spread":"0.23950"},{"groupId":"OG001","value":"0.1142","spread":"0.26247"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1214","spread":"0.20634"},{"groupId":"OG001","value":"0.0366","spread":"0.26470"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1068","spread":"0.21395"},{"groupId":"OG001","value":"0.0321","spread":"0.23607"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0594","spread":"0.26864"},{"groupId":"OG001","value":"0.0658","spread":"0.24229"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0853","spread":"0.24019"},{"groupId":"OG001","value":"0.1066","spread":"0.25848"}]}]}]},{"type":"SECONDARY","title":"Time to Spleen and Disease Progression Free Survival (SDPFS)","description":"Time from randomization to death due to any reason or disease progression (modified IWG-MRT 2013 including ≥ 25% increase in spleen volume by MRI/CT).","classes":[]},{"type":"SECONDARY","title":"Overall Survival","description":"Time from randomization to death due to any reason","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":72,"n":134},"commonTop":["Anaemia","Diarrhoea","Nausea","Thrombocytopenia","Asthenia"]}}}